Phospholipase A 2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes

Circulation

Volumn 125, Issue 6, 2012, Pages 757-766

  Ryu, Sung Kee ^a   Mallat, Ziad ^b   Benessiano, Joelle ^a,c   Tedgui, Alain ^c   Olsson, Anders G ^d   Bao, Weihang ^e   Schwartz, Gregory G ^f   Tsimikas, Sotirios ^g  

^a Eulji University   (South Korea)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d LINKÖPING UNIVERSITY   (Sweden)

^e PFIZER INC   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute coronary syndrome; Hydroxymethylglutaryl CoA reductase inhibitors; Lipoproteins; Oxidation reduction; Phospholipases

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; SECRETORY PHOSPHOLIPASE A2; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEPTANOIC ACID DERIVATIVE; LIPOPROTEIN; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; AGED; ATHEROSCLEROSIS; BLOOD; DOUBLE BLIND PROCEDURE; ENZYMOLOGY; FOLLOW UP; HYPERCHOLESTEROLEMIA; INFLAMMATION; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OXIDATION REDUCTION REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICS; SURVIVAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACUTE CORONARY SYNDROME; AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; PHOSPHOLIPASES A2, SECRETORY; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84857640882     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.063487     Document Type: Article

References (28)

1. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation. 2010; 122: 2183-2200.
2. Stafforini DM. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther. 2009; 23: 73-83.
3. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007; 27: 2094-2099. (Pubitemid 350287235)
4. Karabina SA, Brocheriou I, Le Naour G, Agrapart M, Durand H, Gelb M, Lambeau G, Ninio E. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB. 2006; 20: 2547-2549.
5. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006; 26: 2523-2529. (Pubitemid 44607475)
6. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J. Lipoprotein-associated phospho-lipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375: 1536-1544.
7. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and Its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation. 2006; 113: 1745-1752. (Pubitemid 43958467)
8. Oldgren J, James SK, Siegbahn A, Wallentin L. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. Eur Heart J. 2007; 28: 699-704. (Pubitemid 46439239)
9. Mallat Z, Steg P, Benessiano J, Tanguy ML, Fox KA, Collet JP, Dabbous OH, Henry P, Carruthers KF, Dauphin A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005; 46: 1249-1257. (Pubitemid 41615545)
10. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005; 182: 193-198. (Pubitemid 41188387)
11. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004; 109: 837-842. (Pubitemid 38252734)
12. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008; 51: 1653-1662. (Pubitemid 351626406)
13. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711-1718. (Pubitemid 32259905)
14. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, Cohen A, Huart V, Wareham NJ, Luben R, Khaw KT, Tedgui A, Boekholdt SM. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK Study. Arterioscler Thromb Vasc Biol. 2007; 27: 1177-1183. (Pubitemid 46641976)
15. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoproteinassociated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006; 26: 1586-1593. (Pubitemid 44288987)
16. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010; 56: 946-955.
17. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005; 25: 839-846. (Pubitemid 40463879)
18. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999; 100: 1280-1284. (Pubitemid 29440119)
19. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286: 64-70. (Pubitemid 32606333)
20. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27: 2236-2243. (Pubitemid 350287255)
21. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005; 51: 2264-2273. (Pubitemid 41692569)
22. Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, Tsimikas S. Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol. 2011; 5: 50-56.
23. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S. Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J. 2009; 30: 107-115.
24. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med. 2011; 5: 673-694.
25. Ravandi A, Boekholdt SM, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011; 52: 1829-1836.
26. Weismann D, Hartvigsen K, Lauer N, Bennett KL, Scholl HP, CharbelIssa P, Cano M, Brandstatter H, Tsimikas S, Skerka C, Superti-Furga G, Handa JT, Zipfel PF, Witztum JL, Binder CJ. Complement factor Prof. binds malondialdehyde epitopes and protects from oxidative stress. Nature. 2011; 478: 76-81.
27. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S. Oxidized phospholipids, lipoprotein (a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007; 27: 1788-1795. (Pubitemid 47207175)
28. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2009; 23: 93-101.